Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | PNMT | P11086 | 3/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30528615 | 1.00 | TAAR1 (0.54) | TAAR1TSHRDPP4PNMTNR4A2 | |
| SCHEMBL110460 | 0.85 | TAAR1 (0.64) | TAAR1TSHRDPP4PNMTCYP3A4 | |
| SCHEMBL11758388 | 0.83 | TSHR (0.52) | TAAR1TSHRDPP4PNMTNR4A2 | |
| Hydrochloric Acid SCHEMBL7895201 | 0.82 | TAAR1 (0.61) | TAAR1TSHRDPP4PNMTCYP3A4 | |
| Hydrochloric Acid SCHEMBL460781 | 0.79 | CYP3A4 (0.43) | TAAR1TSHRDPP4PNMTALDH1A1 | |
| SCHEMBL1372359 | 0.79 | TSHR (0.48) | TAAR1TSHRDPP4PNMTNR4A2 | |
| SCHEMBL2911470 | 0.79 | TSHR (0.48) | TAAR1TSHRDPP4PNMTNR4A2 | |
| SCHEMBL3791097 | 0.79 | ALDH1A1 (0.52) | TAAR1TSHRDPP4PNMTNR4A2 | |
| SCHEMBL11571234 | 0.79 | TSHR (0.48) | TAAR1TSHRDPP4PNMTNR4A2 | |
| SCHEMBL29701394 | 0.79 | ALDH1A1 (0.52) | TAAR1TSHRDPP4PNMTNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101203244-A | Compositions of rennin inhibitor and insulin secernent or insulin sensitizer | NOVARTIS AG (CH) | 2008-06-18 | — | — | CN | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| CN-115925642-B | Synthesis method of 1, 4-benzodiazepine Zhuo Zahuan derivative | 枣庄学院 | 2025-02-07 | — | — | CN | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| CN-115925642-A | Synthesis method of 1, 4-benzodiazepine heterocyclic derivative | 枣庄学院 | 2023-04-07 | — | — | CN | disclosed |
| WO-2022064075-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2022-03-31 | — | — | WO | disclosed |
| CN-111925334-B | Synthetic method of 5H-1, 4-benzodiazepine compound | 扬州大学 | 2021-11-23 | — | — | CN | disclosed |
| CN-111925334-A | Synthetic method of 5H-1, 4-benzodiazepine compound | 扬州大学 | 2020-11-13 | — | — | CN | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20060252779-A1 | (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006108773-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-INDAN-1-YL-AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229323-A1 | (3,4-Dihydro-quinazolin-2-yl)-indan-1-yl-amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | disclosed |
| US-20060211716-A1 | (3,4-Dihydro-quinazolin-2-yl)-aryl-amines | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-09-21 | — | — | US | disclosed |
| WO-2006097391-A1 | USE OF 2 -ANILINO - 3 , 4 -DIHYDRO - QUINAZOLINES AS 5HT5A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF | 2005-04-14 | — | — | US | disclosed |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) | 2005-02-24 | — | — | US | disclosed |
| EP-1348707-A1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) (CZ) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211716-A1 | (3,4-Dihydro-quinazolin-2-yl)-aryl-amines | HTR5A, HTR1A, HTR2C | TAAR1 74/4885TSHR 317/4885DPP4 1008/4885 |
| US-20060229323-A1 | (3,4-Dihydro-quinazolin-2-yl)-indan-1-yl-amines | HTR5A, HTR1A, HTR1E | TAAR1 71/4885TSHR 108/4885DPP4 2648/4885 |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | CBR3, DHFR, AKR1C3 | TAAR1 705/4885TSHR 51/4885DPP4 3429/4885 |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ATIC, UMPS, CCNB1 | TAAR1 3350/4885TSHR 1625/4885DPP4 4483/4885 |
| US-20060252779-A1 | (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HTR5A, NPY5R, HTR3A | TAAR1 50/4885TSHR 148/4885DPP4 1321/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | TAAR1 2787/4885TSHR 1575/4885DPP4 3718/4885 |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | CDK8, CDK6, CDK1 | TAAR1 1013/4885TSHR 2431/4885DPP4 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.